Skip to Main Content

Matthew A. Gubens


Thoracic medical oncologist

Dr. Matthew Gubens is a thoracic oncologist, or lung cancer specialist. He specializes particularly in treating non–small cell lung cancer, small cell lung cancer, thymoma and thymic carcinoma, and mesothelioma. He sees patients in the UCSF Thoracic Surgery and Oncology Clinic at the Helen Diller Family Comprehensive Cancer Center.

In his research, Gubens studies lung cancer and new treatment strategies.

Gubens earned his medical degree at Stanford University School of Medicine. He completed a residency in internal medicine at UCSF Medical Center and a fellowship in medical oncology at Stanford. He also has a master of science degree from the Harvard T.H. Chan School of Public Health.

Gubens is a member of the American Society of Clinical Oncology, International Association for the Study of Lung Cancer, International Thymic Malignancy Interest Group and American College of Physicians.

  • Education

    Harvard School of Public Health, Master of Science, 2000

    Stanford School of Medicine, 2005

  • Residencies

    UCSF Medical Center, Internal Medicine, 2008

  • Fellowships

    Stanford University, Medical Oncology, 2011

  • Board Certifications

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Associate Professor

Where I see patients (2)

    My reviews


    Overall Experience
    217 Ratings
    Explained things in a way that was easy to understand
    216 Ratings
    Did the doctor pay attention to your concerns
    217 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    211 Ratings
    Knew the important information about your medical history
    213 Ratings
    The provider showed respect for what you had to say
    215 Ratings
    The provider spent enough time with me
    213 Ratings

    Selected research

    Decorative Caduceus

    Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak ...


    Decorative Caduceus

    A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Ad...

    DLTs are defined as certain non-hematologic and hematologic toxicities of Grade 3 or higher.